Active Protocol
Auto-saved to your account
Loaded from saved
Phase
Patients
Similar Trials
Risk Score
Claude Sonnet
Input tokens:
Output tokens:
Cost:
OpenAI Embeddings
Tokens:
Cost:
Total Analysis
API Calls:
Total tokens:
Total Cost:
My Saved Analyses
v
+ more
Overall Risk
Based on similar trials analysis
Amendment Risk
Predicted amendments:
Protocol Complexity
Similar Trial Success
Completion rate in similar trials
Critical Warnings
HIGH
Competitive Landscape
Similar Trials
Competing (Recruiting)
Competition Level
Enrollment Forecast
Target
Est. Duration (Base)
Benchmark
Site Strategy
Recommended Sites
Countries
Pts/Site Target
Additional Recommendations
Protocol Strengths
+
Detected Therapeutic Area:
Total Matched:
Showing:
Mechanism of Action Breakdown
Sponsor Track Record
Total Trials
Completion Rate
Termination Rate
In This Area
Competitive Assessment
Key Implications
- •
Competitor Analysis
trials
Strengths:
Weaknesses:
Enrollment Competition Analysis
Competing Trials
Competition Intensity
Timeline Impact
Geographic Hotspots
Underserved Regions
Mitigation Strategies
- ✓
Differentiation Analysis
Your Unique Factors
Potential Disadvantages
Strategic Recommendations
Top Sponsors in Similar Trials
Organizations leading the most similar trials in this therapeutic area
trials
Sponsor analysis based on similar trials not yet available.
Competitive Monitoring Plan
Key Competitors to Watch
- •
Key Milestones to Track
- ●
Recommended Frequency:
No trials match your filter criteria.
Amendment Risk
Complexity Score
Similar Trial Success
Trials Analyzed
Design vs. Successful Trials
| Metric | Yours | Benchmark |
|---|---|---|
Top Amendment Risk Drivers
Protocol Complexity Analysis
Complexity Score
Complexity Factors
Simplification:
Design Strengths
✓
Leverage:
Design Weaknesses
Action:
Success Prediction Analysis
Predicted Success
Phase Benchmark
TA Benchmark
vs. Average
Key Success Drivers
- ✓
Key Risk Drivers
- ✗
Learnings from Terminated Trials
Prevention:
AI-Powered Recommendations
Evidence
Implementation
Screen Failure Prediction
Predicted Ratio
Benchmark
Best in Class
Your Exclusions
Your Criteria vs Similar Trials
| Criterion | Your Value | % Similar |
|---|---|---|
Patient Pool Estimation
Global Estimate
Primary Screen Failure Drivers
Inclusion Criteria Assessment
Problematic Criteria
Exclusion Criteria Assessment
Problematic Criteria
Eligibility Optimization Recommendations
Your eligibility criteria are well-aligned with similar trials. No major optimization suggestions.
Special Populations Considerations
Elderly
Pediatric
Pregnancy
Comorbidities
Recommendations
- •
Regulatory Alignment
FDA Guidance Alignment
EMA Requirements
Your Primary Endpoint
FDA Alignment:
EMA:
Primary Endpoint Analysis
Type
Measurement Complexity
Assessment Frequency
Overall Assessment
Strengths
- ✓
Weaknesses
- ✗
Regulatory Alignment Details
Relevant FDA Guidance
Precedent Approvals
Recommendations for Better Alignment
- •
Primary Endpoint Types in Similar Trials
Enrollment Comparison with Similar Trials
Your Target
Similar Trial Mean
Median
Min
Max
Sample Size Scenarios
| Scenario | Control Rate | Treatment Rate | Effect Size | N Needed | Power |
|---|---|---|---|---|---|
Statistical Assumptions
Alpha (Type I Error)
Statistical Power
Expected Dropout Rate
Analysis Method
Sample Size Insights
Your Target vs. Similar Trials
Recommendation
Interim Analysis
Sample Size Risks
- ⚠
Secondary Endpoints Analysis
Recommended Additional Endpoints
Endpoint Collection Burden Assessment
Patient Burden
Site Burden
Simplification Opportunities
- ✓
Amendment Risk Score
Predicted Amendments
Industry Benchmark
Trials Analyzed
Risk Factors
Mitigation Strategy
probability
Likely Amendment Areas
Prevention:
Amendment Impact Assessment
Historical Patterns from Similar Trials
Common Triggers
- ⚠
Prevention Strategies
- ✓
Recommended Site Strategy
Recommended Sites
Countries
Pts/Site Target
Benchmark Avg
Activation
Key Strategic Considerations
- •
Geographic Strategy
Primary Regions
Emerging Regions to Consider
Country Recommendations
| Country | Priority | Sites | Patients | Cost | Key Advantages |
|---|---|---|---|---|---|
Must-Have Criteria
- ✓
Preferred Criteria
- •
Red Flags
- ✗
Site Performance Benchmarks
Enrollment Rate
Screen Failure
Deviation Threshold
Query Rate
Retention Target
Activation Timeline Strategy
Risk Mitigation Strategy
Backup Sites Recommended
Contingency Countries
Early Warning Indicators
- ⚠
Top Countries in Similar Trials
Sites with Experience in Similar Trials
Budget Considerations
Cost-Effective Regions
High-Cost Regions
Cost Optimization Strategies
- ✓
Timeline Projections
Target Enrollment:
patients
Base Case Assumptions
- •
Scenario Simulator
Enrollment Bottleneck Analysis
!
Mitigation:
Key Enrollment Risks
- ⚠
Acceleration Strategies
- ✓
Enrollment Metrics
Pts/Site/Month
Recommended Sites
Screen Failure Rate
Site Activation
Risk Score
Probability Predictions
Termination Risk
Enrollment Delay (>6mo)
Amendment Required
Key Risk Indicators
Execution Risk
Based on protocol complexity
Competition Level
Recruiting competing trials
Feasibility Score
Likelihood of successful completion
Risk Matrix with Mitigations
| Risk Factor | Prob | Impact | Mitigation |
|---|---|---|---|
Detailed Risk Category Analysis
Key Factors:
- •
Mitigation Strategies:
Critical Watch Items
!
Trigger:
Response:
Monitor:
Risk Mitigation Priority Actions
Owner:
Deadline:
Success Probability Analysis
Predicted Success
Phase Benchmark
Therapeutic Area Avg
Factors Increasing Success
- ✓
Factors Decreasing Success
- ✗
Regulatory Risk Assessment
✓
-